Bivalirudin
Sequentia:D-Phe-Pro Arg-Pro Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Ile-Pro-Glu-Tyr-Leu-OH.
alias:126:PN:WO2004076484PAGE:31 petita dapibus;Angiomax;BG 8967;Bivalirudin;Hirulog; Hirulog 1
Cas No.: 128270-60-0
Formulae hypotheticae: C98H138N24O33
M. Pondus: 2180.29
Puritas (HPLC): 98.0%min.
Aspectus: Alba pulveris
una immunditia (HPLC): 1.0%max
Amino Acidum Compositio: ± X% speculationis
Peptide Content (N%): >80.0%
Aqua Content (Carolus Fischer): <8.0%
TrifluoroAcetate Content(HPIC): >12.0%
MS (ESI): Congruunt
Massa Libra: 95.0~105.0%
Gradus : Pharmaceutical Grade
Repono: Clausa, infra 2 ~ 8℃ conservatio
Usage : Productum hoc maxime ponitur ad therapationem vascularium ne interventalem praebens in curatione anginae instabilis, ischaemicus complicationes ante et after.It vetat et circulationem et concretum thrombin ligatus, dum etiam inhibens thrombin-mediatam platelet activationem et aggregationem.
Bivalirudin (Angiomax sive Angiox, fabricari per medicinam Company) est specifica et convertitur direct thrombin inhibitor (DTI^).
Bivalirudin est DTI quae multas limitationes vincit, cum inhibitoribus obliquis thrombin visis, ut heparin. Bivalirudin est brevis, synthetica peptide id est potentem, valde specifica, et convertitur inhibitor of thrombin. thrombin et circumigendo et concreto inhibet, dum etiam inhibens thrombin-mediatam platelet activationem et aggregationem. Bivalirudin celerem impetum actionis habet et brevem vitam dimidiatam. Ad plasma proteins non obligat (quam thrombin) aut rubrum sanguinem cellulis. Praedictio ergo habet responsionem antithromboticam. Thrombocytopenia/Heparin Thrombosis-Thrombocytopenia syndrome inducta nullum periculum est. (HIT / HITTS). Non requirit cofactor ligamen ut antithrombin et platelets non excitant. Hae notae idealem faciunt bivalirudin alternative ad heparin.
Bivalirudin studia clinica demonstrata eventus constantes affirmativos in aegris cum angina stabilis, instabiles angina (UA), segmentum non-ST elevatio myocardiaca infarctus (NSTEMI), et st-segmentum elevationis myocardialis infarctionis (STEMI) PCI subeundas in * 7 Maior randomized iudiciis
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
